<table>
<thead>
<tr>
<th>Date</th>
<th>Docket No.</th>
<th>Company Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>20170269</td>
<td>G</td>
<td>Kendall Automotive Group, Inc.; David and Lorraine Edmark; Kendall Automotive Group, Inc.</td>
</tr>
<tr>
<td>20170271</td>
<td>G</td>
<td>Ascent Holdings, LLC; Fulcrum BioEnergy, Inc.; Ascent Holdings, LLC.</td>
</tr>
<tr>
<td>20170272</td>
<td>G</td>
<td>JBG SMITH Properties; JBG/Operating Partners, L.P.; JBG SMITH Properties.</td>
</tr>
<tr>
<td>20170280</td>
<td>G</td>
<td>Blue Star Parent, L.P.; Ansira Holdings, LLC; Blue Star Parent, L.P.</td>
</tr>
<tr>
<td>20170289</td>
<td>G</td>
<td>Antelope NewCo, Inc.; AlixPartners Holdings, LLP; Antelope NewCo, Inc.</td>
</tr>
</tbody>
</table>

11/30/2016

<table>
<thead>
<tr>
<th>Date</th>
<th>Docket No.</th>
<th>Company Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>20170159</td>
<td>G</td>
<td>The Hearst Family Trust; GTCR Fund X/A LP; The Hearst Family Trust.</td>
</tr>
<tr>
<td>20170169</td>
<td>G</td>
<td>Insight MB Parent LLC; MB Parent Holdings, LLC; Insight MB Parent LLC.</td>
</tr>
<tr>
<td>20170274</td>
<td>G</td>
<td>Quintiles IMS Holdings, Inc.; Jon C. Anderson; Quintiles IMS Holdings, Inc.</td>
</tr>
<tr>
<td>20170279</td>
<td>G</td>
<td>Calpine Corporation; NAPGS Holdco, LLC; Calpine Corporation.</td>
</tr>
<tr>
<td>20170284</td>
<td>G</td>
<td>CENTRO ARTE SCIENZA E TECNOLOGIA S.R.L.; Nestle S. A.; CENTRO ARTE SCIENZA E TECNOLOGIA S.R.L.</td>
</tr>
<tr>
<td>20170296</td>
<td>G</td>
<td>Bain Capital Fund XI, L.P.; Blue Nile, Inc.; Bain Capital Fund XI, L.P.</td>
</tr>
<tr>
<td>20170298</td>
<td>G</td>
<td>AIPCF VI AIV Moly-Cop (Cayman), LP; Arrium Limited; AIPCF VI AIV Moly-Cop (Cayman), LP.</td>
</tr>
<tr>
<td>20170300</td>
<td>G</td>
<td>Wind Point Partners, VIII-A, L.P.; Michael J. Baab; Wind Point Partners, VIII-A, L.P.</td>
</tr>
<tr>
<td>20170306</td>
<td>G</td>
<td>AIM Marina Holdings, LLC; John D. Brewer, Jr. and Margaret S. Brewer; AIM Marina Holdings, LLC.</td>
</tr>
</tbody>
</table>


Donald S. Clark
Secretary.

[FR Doc. 2016–29771 Filed 12–12–16; 8:45 am]

BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

[Docket No. FDA–2016–E–0625]

Determination of Regulatory Review Period for Purposes of Patent Extension; NUCALA

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for NUCA LA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

DATES: Anyone with knowledge that any of the dates as published (see the SUPPLEMENTARY INFORMATION section) are incorrect may submit either electronic or written comments and ask for a redetermination by February 13, 2017. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 12, 2017. See “Petitions” in the SUPPLEMENTARY INFORMATION section for more information.

ADDRESSES: You may submit comments as follows:

Electronic Submissions
Submit electronic comments in the following way:
• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions
Submit written/paper submissions as follows:
• Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–2016–E–0625 for “Determination of Regulatory Review Period for Purposes of Patent Extension; NUCA LA.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any...
information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6250, Silver Spring, MD 20993, 301–796–3600.

SUPPLEMENTARY INFORMATION:

I. Background

The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product’s regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human biological products, the testing phase begins when the exemption to permit the clinical investigations of the biological product becomes effective and runs until the approval phase begins. The approval phase begins with the initial submission of an application to market the human biological product and continues until FDA grants permission to market the biological product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of the USPTO may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA’s determination of the length of a regulatory review period for a human biological product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA has approved for marketing the human biologic product NUCALA (mepolizumab). NUCALA is indicated for add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Subsequent to this approval, the USPTO received a patent term restoration application for NUCALA (U.S. Patent No. 5,693,323) from GlaxoSmithKline LLC, and the USPTO requested FDA’s assistance in determining this patent’s eligibility for patent term restoration. In a letter dated May 10, 2016, FDA advised the USPTO that this human biological product had undergone a regulatory review period and that the approval of NUCALA represented the first permitted commercial marketing or use of the product. Thereafter, the USPTO requested that FDA determine the product’s regulatory review period.

II. Determination of Regulatory Review Period

FDA has determined that the applicable regulatory review period for NUCALA is 6,862 days. Of this time, 6,496 days occurred during the testing phase of the regulatory review period, while 366 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective: January 22, 1997. The applicant claims January 21, 1997, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 22, 1997. The applicant claims January 21, 1997, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 22, 1997, which was 30 days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human biological product under section 351 of the Public Health Service Act (42 U.S.C. 262): November 4, 2014. FDA has verified the applicant’s claim that the biologics license application (BLA) for NUCALA (BLA 125526) was initially submitted on November 4, 2014.

3. The date the application was approved: November 4, 2015. FDA has verified the applicant’s claim that BLA 125526 was approved on November 4, 2015.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, this determination includes several statutory limitations in its calculations of the actual period for patent term extension.

In its application for patent extension, this applicant seeks 5 years of patent term extension.

III. Petitions

Anyone with knowledge that any of the dates as published are incorrect may submit either electronic or written comments and ask for a redetermination (see DATES). Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must be timely (see DATES) and contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Submit petitions electronically to https://www.regulations.gov at Docket No. FDA—2013–S–0610. Submit written petitions (two copies are required) to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Dated: December 8, 2016.

Leslie Kux,
Associate Commissioner for Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA—2013–N–0764]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Animal Feed Regulatory Program Standards

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information by January 12, 2017.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: